Apalutamide-Induced Pneumonitis Presenting as Severe Hypoxemic Respiratory Failure in Metastatic Prostate Cancer: A Case Report.
Clinicians should be vigilant for signs of pneumonitis in patients receiving apalutamide, as early intervention may improve outcomes.
Where it sits
this study against the rest of the degarelix corpusSummary and findings
A 69-year-old man with metastatic prostate cancer developed suspected apalutamide-induced pneumonitis, presenting as severe hypoxemic respiratory failure. The patient showed improvement after discontinuing apalutamide and starting corticosteroid therapy. This case underscores the need for vigilance regarding pulmonary toxicity in patients on apalutamide.
Abstract
Apalutamide is a widely used second-generation androgen receptor inhibitor for the treatment of metastatic castration-sensitive and nonmetastatic castration-resistant prostate cancer. Although generally well tolerated, rare cases of interstitial lung disease and drug-induced pneumonitis have been reported. Early recognition is critical because of the potential for significant morbidity and mortality. We present a case of suspected apalutamide-induced pneumonitis in a 69-year-old man with metastatic prostate cancer who developed progressive shortness of breath, severe hypoxia, and bilateral ground-glass opacities on imaging. Extensive evaluation excluded infectious, cardiac, and autoimmune etiologies. The patient demonstrated marked clinical and radiographic improvement following the discontinuation of apalutamide and corticosteroid therapy. This case highlights the importance of maintaining a high index of suspicion for drug-induced pulmonary toxicity in patients receiving apalutamide. Prompt diagnosis and early initiation of corticosteroids may significantly improve outcomes.
Background
Apalutamide is a second-generation androgen receptor inhibitor used in prostate cancer treatment. While generally well tolerated, it has been associated with rare cases of interstitial lung disease and pneumonitis. Understanding these adverse effects is crucial due to their potential severity.
Methods
This study is a case report of a 69-year-old male patient with metastatic prostate cancer. The patient developed respiratory symptoms while on apalutamide. Extensive evaluation was conducted to rule out other causes, and treatment involved discontinuation of apalutamide and administration of corticosteroids.
Results
The patient experienced severe hypoxemic respiratory failure with bilateral ground-glass opacities on imaging. Following the discontinuation of apalutamide and initiation of corticosteroid therapy, there was marked clinical and radiographic improvement.
Interpretation
This case adds to the limited literature on apalutamide-induced pneumonitis, highlighting the need for awareness of this potential side effect. While the improvement upon drug discontinuation and steroid treatment is promising, the findings are limited by the single-case nature of the report.
Key findings
- 69-year-old man with metastatic prostate cancer.
- Severe hypoxia and bilateral ground-glass opacities on imaging.
- Improvement after discontinuation of apalutamide and corticosteroid therapy.
Limitations
- Single case report
- No control group
- No statistical analysis
- Findings not generalizable